These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9795391)

  • 1. Identifying the principal protective antigenic determinants of type A botulinum neurotoxin.
    Bavari S; Pless DD; Torres ER; Lebeda FJ; Olson MA
    Vaccine; 1998 Nov; 16(19):1850-6. PubMed ID: 9795391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms.
    Zhao H; Nakamura K; Kohda T; Mukamoto M; Kozaki S
    Jpn J Infect Dis; 2012; 65(2):138-45. PubMed ID: 22446121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.
    Baldwin MR; Tepp WH; Pier CL; Bradshaw M; Ho M; Wilson BA; Fritz RB; Johnson EA; Barbieri JT
    Infect Immun; 2005 Oct; 73(10):6998-7005. PubMed ID: 16177380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regions recognized on the light chain of botulinum neurotoxin type A by T lymphocytes of SJL and BALB/c mice primed with inactivated toxin.
    Oshima M; Aoki KR; Atassi MZ
    Immunobiology; 2014 Dec; 219(12):950-7. PubMed ID: 25151501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.
    Levy R; Forsyth CM; LaPorte SL; Geren IN; Smith LA; Marks JD
    J Mol Biol; 2007 Jan; 365(1):196-210. PubMed ID: 17059824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.
    Yu Y; Shi D; Liu S; Gong ZW; Wang S; Sun Z
    Hum Vaccin Immunother; 2015; 11(2):468-73. PubMed ID: 25483668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.
    Smith TJ; Lou J; Geren IN; Forsyth CM; Tsai R; Laporte SL; Tepp WH; Bradshaw M; Johnson EA; Smith LA; Marks JD
    Infect Immun; 2005 Sep; 73(9):5450-7. PubMed ID: 16113261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin.
    Ayyar BV; Tajhya RB; Beeton C; Atassi MZ
    Sci Rep; 2015 Oct; 5():15776. PubMed ID: 26508475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A.
    Atassi MZ; Dolimbek BZ
    Protein J; 2004 Jan; 23(1):39-52. PubMed ID: 15115181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.
    Atassi MZ; Jankovic J; Steward LE; Aoki KR; Dolimbek BZ
    Immunobiology; 2012 Jan; 217(1):17-27. PubMed ID: 21962573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibodies of botulinum neurotoxin serotype A screened from a fully synthetic human antibody phage display library.
    Yu R; Wang S; Yu YZ; Du WS; Yang F; Yu WY; Sun ZW
    J Biomol Screen; 2009 Sep; 14(8):991-8. PubMed ID: 19726786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an Equine Antitoxin by Immunizing the Halla Horse with the Receptor-Binding Domain of Botulinum Neurotoxin Type A1.
    Kim NY; Park KE; Lee YJ; Kim YM; Hong SH; Son WR; Hong S; Lee S; Ahn HB; Yang J; Seo JP; Lim YK; Yu CH; Hur GH; Jeong ST; Lee HS; Song K; Kang TJ; Shin YK; Choi JS; Choi JY
    J Microbiol Biotechnol; 2019 Jul; 29(7):1165-1176. PubMed ID: 31280529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species.
    Atassi MZ; Dolimbek BZ; Hayakari M; Middlebrook JL; Whitney B; Oshima M
    J Protein Chem; 1996 Oct; 15(7):691-700. PubMed ID: 8968960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B).
    Shearer JD; Vassar ML; Swiderski W; Metcalfe K; Niemuth N; Henderson I
    Vaccine; 2010 Oct; 28(45):7313-8. PubMed ID: 20816903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid.
    Rosenberg JS; Middlebrook JL; Atassi MZ
    Immunol Invest; 1997 Jun; 26(4):491-504. PubMed ID: 9246568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel platform for engineering stable and effective vaccines against botulinum neurotoxins A, B and E.
    Liu Y; Liu X; Chen W; Yu Y; Meng J; Wang J
    Front Immunol; 2024; 15():1469919. PubMed ID: 39315101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
    Höltje M; Schulze S; Strotmeier J; Mahrhold S; Richter K; Binz T; Bigalke H; Ahnert-Hilger G; Rummel A
    Toxicon; 2013 Dec; 75():108-21. PubMed ID: 23817019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-route targeted vaccine protects efficiently against botulinum neurotoxin A complex.
    Sahay B; Colliou N; Zadeh M; Ge Y; Gong M; Owen JL; Valletti M; Jobin C; Mohamadzadeh M
    Vaccine; 2018 Jan; 36(1):155-164. PubMed ID: 29180028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune recognition of botulinum neurotoxin type A: regions recognized by T cells and antibodies against the protective H(C) fragment (residues 855-1296) of the toxin.
    Oshima M; Hayakari M; Middlebrook JL; Atassi MZ
    Mol Immunol; 1997 Oct; 34(14):1031-40. PubMed ID: 9488054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen.
    Gao YL; Gao S; Kang L; Nie C; Wang JL
    Hum Vaccin; 2010 Jun; 6(6):462-6. PubMed ID: 20519939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.